Page last updated: 2024-09-05

bathocuproine disulfonate and molybdenum

bathocuproine disulfonate has been researched along with molybdenum in 2 studies

Compound Research Comparison

Studies
(bathocuproine disulfonate)
Trials
(bathocuproine disulfonate)
Recent Studies (post-2010)
(bathocuproine disulfonate)
Studies
(molybdenum)
Trials
(molybdenum)
Recent Studies (post-2010) (molybdenum)
1030258,660533,221

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Prosser, RA; Yamada, Y1
Cui, H; Geraghty, D; Guven, N; Liu, JJ; McKeage, MJ; Nott, LM; Zhang, AJ1

Other Studies

2 other study(ies) available for bathocuproine disulfonate and molybdenum

ArticleYear
Copper chelation and exogenous copper affect circadian clock phase resetting in the suprachiasmatic nucleus in vitro.
    Neuroscience, 2014, Jan-03, Volume: 256

    Topics: Animals; Carbazoles; Chelating Agents; Circadian Clocks; Copper; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Glutamic Acid; In Vitro Techniques; Indole Alkaloids; Male; Mice; Mice, Inbred C57BL; Molybdenum; Phenanthrolines; Quinoxalines; Suprachiasmatic Nucleus; Valine

2014
Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity.
    Journal of inorganic biochemistry, 2017, Volume: 177

    Topics: Antineoplastic Agents; Cation Transport Proteins; Cell Line, Tumor; Chelating Agents; Copper; Copper Transporter 1; Copper-Transporting ATPases; Drug Synergism; Humans; Molybdenum; Organoplatinum Compounds; Oxaliplatin; Penicillamine; Phenanthrolines; Up-Regulation

2017